Complete Your CE Test Online - Click Here 33. Mastropietro, D. J., & Omidian, H. (2013). Current approaches in tamper-resistant and abuse- deterrent formulations. Drug Development and Industrial Pharmacy, 39(5), 611–624. doi: 10.3109/03639045.2012.680468 34. Fishman, S. M., Wilsey, B., Yang, J., et al. (2000). Adherence monitoring and drug surveillance in chronic opioid therapy. Journal of Pain and Symptom Management, 20, 293–307. doi: http://dx.doi. org/10.1016/S0885-3924(00)00195-0 35. Chou, R., Gilbert, J., Fanciullo, P. G., et al. (2009). Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. The Journal of Pain, 10(2), 113–130. doi:10.1016/j. jpain.2008.10.008 36. Medscape. (2004). New strategies for managing acute pain episodes in patients with chronic pain. Retrieved from http://www.medscape.org/viewarticle/484371 37. American Medical Association. (2007). The physician’s role in medication reconciliation. Retrieved fromhttps://bcpsqc.ca/documents/2012/09/AMA-The-physician’s-role-in-Medication-Reconciliation. pdf https://bcpsqc.ca/d 38. Benyamin, R., Trescot, A. M., Datta, S, et al. (2008). Opioid complications and side effects. Pain Physician, 11(2 Suppl.), S105–120. 39. Broussard, C. S., Rasmussen, S. A., Reefhuis, J., et al. (2011). Maternal treatment with opioid analgesics and risk for birth defects. American Journal of Obstetrics & Gynecology, 204(314), e1-11. 40. PainEdu. (2016). Chronic opioid therapy: Driving and work safety. Retrieved from https://www. painedu.org/articles_timely.asp?ArticleNumber=31 41. De Maddalena, C., Bellini, M., Berra, M., et al. (2012). Opioid-induced hypogonadism: Why and how to treat it. Pain Physician, 15(3 Suppl.), ES111–8. 42. Fine, P. G., Portenoy, R .K., & the Ad Hoc Expert Panel on Evidence Review and Guidelines for Opioid Rotation. (2009). Establishing “best practices” for opioid rotation: Conclusions of an expert panel. Journal of Pain Symptom Management, 38(3), 418–425. doi:10.1016/j. jpainsymman.2009.06.002 43. Indian Health Service. (2016). Nonadherent patients. Retrieved from http://www.ihs.gov/ painmanagement/monitoring/nonadherentpatients/http://www.ihs.gov/p 44. Potter, J. S., & Marino, E. N. (2013). How to avoid opioid misuse: These practical strategies will help you to identify and monitor the risk of opioid analgesic misuse. Chronic Pain Perspectives, 62(3), S2–S7. 45. Krueger, C. (2015). Methadone for pain management. Practical Pain Management. Retrieved from http://www.practicalpainmanagement.com/treatments/pharmacological/opioids/methadone-pain- management 46. Main, D. (2011). Methadone, used to treat pain, kills thousands every year, Discover. Retrieved from http://blogs.discovermagazine.com/80beats/2011/12/20/methadone-used-to-treat-pain-kills-thousands- every-year/http://blogs.discove 47. Toombs, J. D., & Kral, L. A. (2005). Methadone treatment for pain states. American Family Physician, 71(7),1353–1358. Retrieved from http://www.aafp.org/afp/2005/0401/p1353.html 48. U.S. Food and Drug Administration. (2006). Information for health care professionals methadone hydrochloride. Retrieved from http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm142841.htm 49. Harvard Pilgrim Health Plan. (2015). The safe storage and disposal of opioids. Retrieved from https:// www.harvardpilgrim.org/portal/page?_pageid=253,7304041&_dad=portal&_schema=PORTAL 50. Massachusetts Medical Society. (2016). Medication disposal. Retrieved from http://www.massmed. org/Patient-Care/Health-Topics/Opioids/Medication-Disposal/ 51. U.S. Drug Enforcement Administration, Office of Diversion Control. (2016). National take-back initiative. Retrieved from http://www.deadiversion.usdoj.gov/drug_disposal/takeback/index.html 52. Boyer, E. W. (2012). Management of opioid analgesic overdose. New England Journal of Medicine, 367(2), 146–155. doi:10.1056/NEJMra1202561 53. Miller, S. (2015). Over-the-counter naloxone is ‘a great thing,’ docs say. Live Science. Retrieved from http://www.livescience.com/52351-overdose-drug-naloxone-no-prescription.htmlhttp://www.livescien 54. U.S. Food and Drug Administration. (2012). Naloxone expanded access: OTC status: Considerations for a nonprescription drug development program. Retrieved from http://www.fda.gov/downloads/ Drugs/NewsEvents/UCM300875.pdf 55. U.S. Food and Drug Administration. (2015). FDA blueprint for prescriber education for extended- release and long-acting opioid analgesics. Retrieved from http://www.accessdata.fda.gov/drugsatfda_ docs/rems/ERLA_opioid_2015-08-13_FDA_Blueprint.pdf 56. North Carolina Medical Board. (2014). Policy for the use of opiates for the treatment of pain. Retrieved from http://www.ncmedboard.org/images/uploads/other_pdfs/Policy_for_the_Use_of_ Opiates_for_the_Treatment_of_Pain_June_4_2014.pdf 57. DiPiro, J. T, et al. (2011). Pharmacotherapy: A pathophysiologic approach (8th ed.). New York: McGraw-Hill. 58. Substance Abuse and Mental Health Services Administration. (2012). Older Americans behavioral health issue brief 5: Prescription medication misuse and abuse among older adults. Retrieved from https://www.ncoa.org/resources/issue-brief-5-prescription-medication-misuse-and-abuse-among-older- adults/. 59. Centers for Disease Control and Prevention. (2016). Checklist for prescribing opiates for chronic pain. Retrieved from http://www.cdc.gov/drugoverdose/pdf/pdo_checklist-a.pdf PRESCRIBING CONTROLLED SUBSTANCES AND PREVENTING DRUG DIVERSION FOR WEST VIRGINIA NURSES Self-Evaluation Exercises Select the best answer for each question and check your answers at the bottom of the page. You do not need to submit this self-evaluation exercise with your participant sheet. 1. The primary purpose of the 1970 Controlled Substances Act is to: a. Regulate controlled substances in the United States. b. Prosecute illegal drug use in the United States. c. Monitor drug trafficking in the United States. d. Regulate the cost of controlled substances in the United States. 2. According to the Controlled Substance Act, what schedule is methylphenidate categorized in? a. Schedule I. b. Schedule II. c. Schedule III. d. Schedule IV. 3. What DEA form should be used by a practitioner to apply for DEA Registration? a. DEA Form 222. b. DEA Form 223. c. DEA Form 224. d. DEA Form 71. 4. Under which of the following circumstances may a Schedule II prescription be faxed to a pharmacy? a. If the patient is in a hospice program. b. If the patient is under 6 years old. c. If the patient is in the emergency room. d. If the patient is over 85 years old. 5. Which of the following is NOT considered prescription misuse by a patient? a. Taking higher doses than prescribed. b. Taking opiates long-term. c. Used for purposes other than prescribed use. d. Skipping doses/hoarding drug. 6. Which of the following is NOT a common characteristic of a drug abuser? a. Assertive personality, often demanding immediate action. b. Will often request a specific controlled drug and is reluctant to try a different drug. c. Refills pain medication late. d. May exaggerate medical problems and/or simulate symptoms. 7. Which of the following is NOT something that should be done when confronted by a suspected drug abuser? a. Dispense drugs just to get rid of drug-seeking patients. b. Document exam results and questions you asked the patient. c. Request picture ID, or other ID and a Social Security number. Photocopy these documents and include in the patient’s record. d. Call a previous practitioner, pharmacist or hospital to confirm patient’s story. 8. All of the following are general principles of responsible controlled substance prescribing EXCEPT: a. Informed consent. b. Periodic review. c. Treatment plan. d. Answers to patient questions about insurance coverage. 9. Which of the following pieces of information does NOT need to be added to the patient’s medical record when performing controlled substance evaluations? a. Diagnostic, therapeutic, and laboratory results. b. Evaluations and consultations. c. Insurance coverage. d. Treatment objectives. 10. When counseling patients on proper use of controlled substances, all of the following should be conveyed to the patient EXCEPT: a. Never use medicines after the expiration date. b. Never share medicines with others. c. Transdermal patches may be worn in MRI scanners. d. Do not take medication with alcohol or other sedatives. Answers: 1.A 2.B 3.C 4.A 5.B 6.C 7.A 8.D 9.C 10.C Page 8 nursing.elitecme.com